Simavita Limited

Simavita Limited

February 04, 2015 11:29 ET

Simavita Limited: Philippa Lewis Discusses the Abena Distribution Agreement and Appendix 4C

SYDNEY, AUSTRALIA--(Marketwired - Feb. 4, 2015) - Simavita Limited (ASX:SVA)(TSX VENTURE:SV) ("Simavita" or the "Company") is pleased to invite investors to listen to an audio recording of CEO, Ms. Philippa Lewis, providing further background to the Company's announcement released on January 29, 2015, entitled "Simavita signs up Danish distributor", and the Company's quarterly cash flow report, which was released on January 30, 2015.

In this audiocast, Ms. Lewis discusses the following:

  • An overview of the Danish distribution agreement with Abena A/S, and what makes Abena a good fit from a distribution perspective;
  • Further detail around the standard of aged care in Denmark;
  • Progress on the showcase site established in Denmark and resulting revenues for Simavita; and
  • An overview of the key numbers reported in the Appendix 4C for the period ended December 31, 2014.

To listen to the audiocast, please copy the following link into your browser:

About Simavita

Simavita is a medical device company operating in the digital healthcare sector that has developed an innovative, world first solution for the management of urinary incontinence, with a focus on the elderly. The first product is the SIM™ platform technology which is an instrumented incontinence assessment application that provides evidence based incontinence management care plans to the residential aged care market.

About SIM

SIM™ is a wireless sensor technology that delivers evidence-based instrument incontinence data on individuals. SIM™ provides user friendly tools and software to assess the incontinence condition and to help plan better outcomes. SIM™ is used to detect, record and report incontinence events during a compulsory or recommended assessment period in residential aged care facilities to develop an evidence-based incontinence care plan.

Conducting assessments is mandatory in many countries and the incontinence assessment creates an influential element of care of each individual. For more information on Simavita or SIM™, please visit

The TSX Venture Exchange has in no way passed upon the merits of the transactions set out herein and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange not its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this Release.

Except for historical information, this announcement may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, the anticipated date of on the ASX, changing market conditions, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

Simavita Limited ARBN 165 831 309

Contact Information